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 Model Overview
 Model Results


PSORIATIC ARTHRITIS
DISEASE BRIEF

PSA IS A CHRONIC INFLAMMATORY DISEASE OF THE JOINTS
AND SKIN RESULTING FROM AN UNCONTROLLED IMMUNE
RESPONSE1
Bone Remodeling4

Pain and Swelling of Joints,
Enthesitis, Dactylitis3

Osteoclasts

Inflammation

Local Inflammation2
PDE4
cAM
P

AM
P

Pro-Inflammatory
Mediators

Systemic
Inflammation2

Immune Cell

Over-production of TNF-α as well as other cytokines, alters bone
homeostasis, resulting in the joint damage seen in PsA4
1.
2.
3.
4.

Schafer. Biochem Pharmacol. 2012;83:1583
Serezani et al. Am J Respir Cell Mol Biol. 2008;39:127
Gottlieb et al. J Am Acad Dermatol. 2008;58:851
Mensah et al. Curr Rheumatol Rep. 2008;10(4):311

PSA DIFFERS FROM RHEUMATOID ARTHRITIS (RA) BASED
ON THE PRESENCE OF PSORIATIC-ASSOCIATED CONDITIONS
AND THE DISTRIBUTION AND APPEARANCE OF THE
AFFECTED JOINTS
Clinical
Feature
Psoriatic skin
lesions present
Psoriasisassociated nail
symptoms
Distribution of
affected joints
Appearance of
the affected joint

Disease
progression
Rheumatoid
factor status

PsA

RA

Common

No

Common

No

Often asymmetrical
Various joints affected

Symmetrical
Primarily involving hands and
wrists
Pronounced swelling over joints
(RA nodules)

More generalized swelling
Produce a sausage-like
appearance in fingers or toes
Variable
Seronegative

3. Gottlieb A, et al. J Am Acad Dermatol. 2008 May;58(5):851-64.

Predictable
Seropositive

KEY CONCEPTS
• In 75% of cases, psoriasis precedes the
joint disease.
• In 15% of cases, the onset of skin disease
is at the same time as onset of joint
involvement.
• In 10% of cases, the joint disease precedes
the psoriasis.

PSA AND QOL






For people with psoriatic arthritis, quality of life is impacted by
both the physical symptoms of the disease and the emotional
burden of sometimes disfiguring skin symptoms.
Compared to rheumatoid arthritis and ankylosing spondylitis,
people with psoriatic arthritis report more psychosocial problems.
This finding fits with data from a survey of people with psoriasis,
which found that 75 percent of patients believe the skin condition
had a moderate to large negative impact on their quality of life,
with alteration in their activities and work.

5. Husted JA, et al. Arthritis Rheum. Apr 2001;45(2):151-158.
6. Salaffi F, et al. Health Qual Life Outcomes. 2009;7:25.
7. Bhosle MJ, et al. Health Qual Life Outcomes. 2006;4:35.

PSA HAS A SIGNIFICANT NEGATIVE IMPACT
ON HEALTH-RELATED QUALITY OF LIFE
(HRQOL)
•

Decreased QoL as measured by the Medical Outcomes Short-Form 36
Questionnaire (SF-36) scores in patients with PsA compared to the
general population:1

•

19% of patients with PsA claimed their disease resulted in “marked
physical limitations”2

•

8.2% of patients sought assistance for home activities from friends or
family3

•

Both physical functioning and emotional well-being are decreased.

•

In patients with PsA and psoriasis:
– Arthritis component - greater impact on physical functioning
– Psoriasis component - greater impact on emotional well-being
• Skin lesions associated with poor self-image and distress from pruritus and pain.

8Husted

JA, et al. J Rheumatol. 1997 Mar;24(3):511-7.
Alonso JC, et al. Br J Rheumatol. 1991 Aug;30(4):245-50.
10Kimball AB, et al. J Drugs Dermatol. 2007 Mar;6(3):299-306.
9Torre

8

EPIDEMIOLOGY
Prevalence

5% - 40% of people with psoriasis

Race

Affects Caucasians more than other races

Gender

Men and women equally affected

Age of onset

40–50 years of age, can occur earlier

11. Gladman DD. Rheum Dis Clin North Am 1992;18:247–56

TREATMENT OPTIONS
Mild Disease


NSAIDs

Moderate to Severe Disease


Corticosteroids



Traditional DMARDs






MTX
Sulfasalazine
Leflunomide

Biologic DMARDs

National Guideline Recommendations in
Patients with PsA
Mild

NSAIDs

DMARDs
-Leflunomide
-Sulfasalazine

PsA Disease
Status
Moderate/
Severe*

TNF inhibitors
-Adalimumab
-Etanercept
-Infliximab

*No evidence supporting DMARDs ahead of TNF inhibitors (effect size: TNF inhibitors >
traditional DMARDs). However, TNF inhibitors are recommended for patients who fail to
respond to at least one DMARD therapy unless poor prognosis present.
Grade A=Based on evidence from meta-analysis of randomized controlled trials (RCT) or ≥ 1 RCT
12. Ritchlin CT, et al. Ann Rheum Dis. 2009 Sept;68(9): 1387-94.



Adverse Effects Limit the Benefits of Therapy
with Traditional Systemic DMARDs and
Biologics
Traditional systemic agents
• Methotrexate (MTX) has weak and conflicting evidence in the
management of PsA with risks of serious toxic reactions.
• MTX is not approved by the FDA
• Leflunomide does not have FDA approval and requires monitoring
for hepatic toxicity
• Sulfasalazine has limited evidence in the management of PsA
with rarely occurring serious toxicities.

 Biologics
• Mild injection-site/infusion reactions
• Black box warning of risk of serious infections and malignancies
- Increased risk of infection
• Overall infections, odds ratio 1.18 (95% confidence
interval, 1.05-1.33)2
- Patients with PsA are at greater risk for mortality from
infection.
13. Enbrel Prescribing Information, http://pi.amgen.com/united_states/enbrel/derm/enbrel_pi.pdf

The Significant Burden Associated with PsA
 Patients with PsA:
• Suffer from limited mobility, pain, inflammation and stiffness
as well as skin lesions from psoriasis
• Have a poorer quality of life
• Are less likely to be employed and less likely to be productive

• Incur higher healthcare costs

 New PsA therapies are needed that demonstrate:
• Effective Treatment in Patients with Active Psoriatic
Arthritis
• Improved Safety and Better Tolerability than Traditional
DMARDS and Biologics

• Patient Convenience over Injectable Biologics
• Cost savings compared to Biologics

APREMILAST
 Apremilast

is a first-in-class PDE4

inhibitor



MOA: modulates pro-inflammatory and antiinflammatory mediators
Administration: oral and does not need dose
adjustments

 This

drug represents a novel treatment
option for patients and can represent a
delay in biologic therapy14

14. Tencer T, et al. (2014) Economic evaluation of sequencing strategies in the treatment of psoriatic arthritis in the
United States (abstract). Value in Health (17)3: A46.

OUTCOME MEASURES OF PSA




ACR response criteria: 20%, 50%, 70%
(validated in RA, not PsA)
 Tender and swollen joint count
(modified for PsA to include DIP and CMC joints: 78/76,
68/66)
 3/5: patient global, physician global, patient pain, HAQ,
acute phase reactant (sed rate, CRP)
Psoriatic Arthritis Response Criteria (PsARC)
 Improvement in at least 2 of 4 criteria, including:








Physician global assessment (0–5)
Patient global assessment (0–5)
Tender joint score ( 30%)
Swollen joint score ( 30%)

Improvement in at least 1 of 2 joint scores
No worsening in any criteria

DISCRETE EVENT SIMULATION

All Models Are Wrong, But
Some Are Useful

-George E.P. Box

DISCRETE EVENT SIMULATION (DES)


DES is a modeling technique that is event-based

Advantages vs Markov Models
 DES can incorporate new data as it becomes
available




Can use an individual patient’s values and
examine the decision from his or her point of view
Can capture multiple events with competing
risks

BASIC MODEL STRUCTURE


Patients with active psoriatic arthritis who have failed
methotrexate (MTX) therapy will be split into two
groups: apremilast followed by best supportive care
(BSC) and patients only receiving BSC
Apremilast

BSC

MTX
Failure
BSC

STEP 1: CREATE PATIENTS AND ASSIGN
CHARACTERISTICS


Assign Baseline Utilities:
Age
 Gender (45% male)
 Life expectancy
 Mortality


STEP 2: PATIENTS ENTER EITHER APR OR
BSC TREATMENT ARM
If ‘Is Patient starting a Trial?’ is TRUE, then
patients enter APR arm
 ‘Assign Time to Event TP’ sets the next event to
death and logs the time at the beginning of the
time-to-event period
 Time advances in “Wait Next Event TP”


STEP 2: PATIENTS ENTER EITHER APR OR
BSC TREATMENT ARM
Patients move to ‘Assign QALYs and Costs TP’
where QALYs and Costs are calculated
 The VBA module is used to calculate Other
Healthcare Costs




The VBA module computes the patient’s age each
month and tallies the costs over the course of the
period

STEP 2: PATIENTS ENTER EITHER APR OR
BSC TREATMENT ARM




After costs and QALYs have been assigned,
‘Death in TP?’ checks to see if the time of death
event was prior to the end of the Trial Period

If so, patient is disposed of in the model,
otherwise patient continues to BSC

STEP 3: DECIDE IF TREATMENT WAS
EFFECTIVE (OR NOT)
Patients enter a decision module (‘DECIDE
outcome of Trial Period’) which decides whether
the patients achieved a PsARC score (effective
treatment) or not
 If treatment effective, patients are assigned to a
PASI group to allocate future costs and QALYs
 Patients who are not successfully treated move to
the BSC arm


STEP 3: DECIDE IF TREATMENT WAS
EFFECTIVE (OR NOT)
‘Assign Time to Event PASI’ module assigns a
length of time until patients move to BSC
 Similar to the Trial Period arm, patient is
advanced in time through the ‘Wait Next Event
PASI’ module to the sooner of either Death or
BSC or model end
 Costs and QALYs are assigned as in Trial Period
arm


STEP 4: BSC, DEATH, OR MODEL END
Patients enter BSC arm either at beginning of
the model run or through discontinuation of
treatment
 Similar to Trial Period and Apremilast Arm, with
patients disposed of at the end
 The Excel read/write modules are also shown


MODEL ASSUMPTIONS
Patients who enter the BSC arm do not go back
to apremilast therapy
 There are no changes to BSC or treatment
paradigms of PsA in clinical practice over the
time horizon of the model (5 years)
 The population to which the model is applied to
follows the age and life expectancy of that in the
model
 HAQ scores return to baseline after
discontinuation of treatment
 No monitoring or lab costs for apremilast


MODEL LIMITATIONS






Data was sourced from clinical trials and not real
world
PASI is used as the trial period endpoint, but is
not the clinical trial endpoint for efficacy
Indirect costs of treatment are not accounted for
in the model

MODEL RESULTS
Comparison of DES to Markov
Model
• Model cost results are within
20%
QALY/
patient

Cost/
patient

Markov
Model

0.29

$41,338

DES

0.86

$33,888

CONCLUSIONS


DES models are more adaptable, compared to
Markov models




DES and Markov models share limitations,
specifically the availability and quality of data




Once data becomes available, for example QOL
instrument data, the DES is easily updated

Markov models have less data requirements

A comparison of two models with the same data
shows differences that can be attributed to
time to event that was used to calculate drop off to
BSC
 distributions used for age and life expectancy
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